JPWO2021209357A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021209357A5 JPWO2021209357A5 JP2022562595A JP2022562595A JPWO2021209357A5 JP WO2021209357 A5 JPWO2021209357 A5 JP WO2021209357A5 JP 2022562595 A JP2022562595 A JP 2022562595A JP 2022562595 A JP2022562595 A JP 2022562595A JP WO2021209357 A5 JPWO2021209357 A5 JP WO2021209357A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- binding protein
- amino acid
- acid sequence
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063009555P | 2020-04-14 | 2020-04-14 | |
| US63/009,555 | 2020-04-14 | ||
| US202063110094P | 2020-11-05 | 2020-11-05 | |
| US63/110,094 | 2020-11-05 | ||
| PCT/EP2021/059377 WO2021209357A1 (en) | 2020-04-14 | 2021-04-12 | Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023521228A JP2023521228A (ja) | 2023-05-23 |
| JP2023521228A5 JP2023521228A5 (https=) | 2024-04-23 |
| JPWO2021209357A5 true JPWO2021209357A5 (https=) | 2024-04-23 |
Family
ID=75497924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022562595A Pending JP2023521228A (ja) | 2020-04-14 | 2021-04-12 | 癌の併用療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230140694A1 (https=) |
| EP (1) | EP4136113A1 (https=) |
| JP (1) | JP2023521228A (https=) |
| CN (1) | CN115698075A (https=) |
| AU (1) | AU2021256652A1 (https=) |
| CA (1) | CA3171557A1 (https=) |
| WO (1) | WO2021209357A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41414A (fr) * | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
| US12162940B2 (en) | 2021-05-05 | 2024-12-10 | Immatics Biotechnologies Gmbh | BMA031 antigen binding polypeptides |
| CN120752053A (zh) * | 2023-03-03 | 2025-10-03 | 正大天晴药业集团南京顺欣制药有限公司 | 含抗tim-3抗体的药物组合 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| JP3871503B2 (ja) | 1999-08-30 | 2007-01-24 | 日本たばこ産業株式会社 | 免疫性疾患治療剤 |
| JP4210454B2 (ja) | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | 炎症性腸疾患治療剤 |
| JP4212278B2 (ja) | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | 移植片拒絶反応抑制剤 |
| US20050053973A1 (en) | 2001-04-26 | 2005-03-10 | Avidia Research Institute | Novel proteins with targeted binding |
| US20050089932A1 (en) | 2001-04-26 | 2005-04-28 | Avidia Research Institute | Novel proteins with targeted binding |
| WO2003042402A2 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| WO2005040229A2 (en) | 2003-10-24 | 2005-05-06 | Avidia, Inc. | Ldl receptor class a and egf domain monomers and multimers |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| EP2068925A4 (en) | 2007-05-07 | 2011-08-31 | Medimmune Llc | ANTI-ICOS ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER, TRANSPLANTATIONS AND AUTOIMMUNE DISEASES |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| JP5794917B2 (ja) | 2008-09-12 | 2015-10-14 | アイシス・イノベーション・リミテッドＩｓｉｓ Ｉｎｎｏｖａｔｉｏｎｌｉｍｉｔｅｄ | Ｐｄ−１特異抗体およびその使用 |
| US8927697B2 (en) | 2008-09-12 | 2015-01-06 | Isis Innovation Limited | PD-1 specific antibodies and uses thereof |
| KR101814408B1 (ko) | 2008-09-26 | 2018-01-04 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도 |
| JP5933975B2 (ja) | 2008-11-12 | 2016-06-15 | メディミューン，エルエルシー | 抗体製剤 |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| CN101898945B (zh) | 2010-07-27 | 2013-05-08 | 大连理工大学 | 盐析萃取发酵液中丙酮和丁醇的方法 |
| ES2612914T3 (es) | 2011-03-31 | 2017-05-19 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Anticuerpos dirigidos contra Icos y usos de los mismos |
| EP2892928B1 (en) | 2012-09-03 | 2018-05-30 | INSERM - Institut National de la Santé et de la Recherche Médicale | Antibodies directed against icos for treating graft-versus-host disease |
| MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
| TWI719970B (zh) | 2015-03-23 | 2021-03-01 | 美商永斯醫療股份有限公司 | 針對ｉｃｏｓ之抗體 |
| EA201792184A1 (ru) * | 2015-04-01 | 2018-04-30 | Анаптисбайо, Инк. | Антитела, направленные против т-клеточного иммуноглобулина и белка муцина 3 (tim-3) |
| WO2018029474A2 (en) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
| WO2018025221A1 (en) * | 2016-08-04 | 2018-02-08 | Glaxosmithkline Intellectual Property Development Limited | Anti-icos and anti-pd-1 antibody combination therapy |
| AU2017321625A1 (en) * | 2016-08-30 | 2019-04-04 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| WO2018045110A1 (en) | 2016-08-30 | 2018-03-08 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| JP7290568B2 (ja) * | 2016-12-20 | 2023-06-13 | カイマブ・リミテッド | 癌免疫療法のための併用療法での多重特異性抗体 |
| MX2019008208A (es) | 2017-01-09 | 2019-12-11 | Tesaro Inc | Métodos para tratar el cáncer con anticuerpos anti-tim-3. |
| TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
| EP3615572A1 (en) * | 2017-04-27 | 2020-03-04 | Tesaro Inc. | Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof |
| EP3634483A1 (en) * | 2017-06-09 | 2020-04-15 | GlaxoSmithKline Intellectual Property Development Limited | Combination therapy |
| TWI852940B (zh) * | 2018-09-04 | 2024-08-21 | 美商泰沙羅公司 | 治療癌症之方法 |
-
2021
- 2021-04-12 AU AU2021256652A patent/AU2021256652A1/en not_active Abandoned
- 2021-04-12 JP JP2022562595A patent/JP2023521228A/ja active Pending
- 2021-04-12 US US17/911,937 patent/US20230140694A1/en not_active Abandoned
- 2021-04-12 WO PCT/EP2021/059377 patent/WO2021209357A1/en not_active Ceased
- 2021-04-12 EP EP21718550.3A patent/EP4136113A1/en not_active Withdrawn
- 2021-04-12 CN CN202180041103.0A patent/CN115698075A/zh active Pending
- 2021-04-12 CA CA3171557A patent/CA3171557A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11168144B2 (en) | Activatable anti-PDL1 antibodies, and methods of use thereof | |
| CN113924318B (zh) | 具有抗BCMA抗体和gamma分泌酶抑制剂的联合疗法 | |
| CN109152798B (zh) | 特异于糖基化的pd-1的抗体及其使用方法 | |
| CN110799543A (zh) | 肝细胞癌的免疫治疗 | |
| CN114044824A (zh) | 用于治疗的抗肾上腺髓质素(ADM)抗体或抗ADM抗体片段或抗ADM非Ig骨架 | |
| US10752688B2 (en) | Anti-human TIM-3 antibodies and methods of use thereof | |
| WO2021216468A1 (en) | Human tigit specific single domain antibodies and methods of use | |
| CN107614530A (zh) | 用于多发性骨髓瘤（mm）的治疗 | |
| WO2020169698A1 (en) | Sensitization of cancer cells to tnf by bet inhibition | |
| WO2013140787A1 (ja) | 特発性炎症性筋疾患の予防又は治療剤 | |
| JP2021530428A (ja) | 頭頸部癌の処置 | |
| WO2022150642A1 (en) | Anti-interleukin 36 receptor (il-36r) therapy for hidradenitis suppurativa | |
| US20230140694A1 (en) | Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies | |
| JPWO2021209357A5 (https=) | ||
| US20250177519A1 (en) | Use of isatuximab in combination with other agents for the treatment of multiple myeloma | |
| KR20210019487A (ko) | 스트레스 관련 장애 및 암의 치료를 위한 물질 및 방법 | |
| WO2023093744A1 (zh) | 一种双特异性抗原结合蛋白 | |
| US20230192833A1 (en) | New anti-VEGFC antibodies and uses thereof | |
| JPWO2021209356A5 (https=) | ||
| US20240287164A1 (en) | Antibodies specific to nell2 and methods of use | |
| HK40106554A (zh) | 用於治疗的抗肾上腺髓质素(adm)抗体或抗adm抗体片段或抗adm非ig骨架 | |
| WO2024112561A1 (en) | Methods for the treatment of myasthenia gravis | |
| HK40069661A (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig scaffold for use in therapy | |
| AU2023374714A1 (en) | Anti-ctla antibody compositions and related methods | |
| CA3064588A1 (en) | Activatable anti-pdl1 antibodies, and methods of use thereof |